

Department of Pharmacology and Experimental Department of Pharmacology and Experimental Therapeutics Faculty Papers Therapeutics

2-17-2020

Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy.

Edwin Lam Thomas Jefferson University

Yi Ting Kayla Lien University of Florida

Walter K. Kraft Thomas Jefferson University

Beth Piraino University of Pittsburgh

Valvanera Vozmediano University of Florida Follow this and additional works at: https://jdc.jefferson.edu/petfp

Part of the Medical Pharmacology Commons See next page for additional authors Let US Know now access to this document benefits you

Recommended Citation

Lam, Edwin; Lien, Yi Ting Kayla; Kraft, Walter K.; Piraino, Beth; Vozmediano, Valvanera; Schmidt, Stephan; and Zhang, Jingjing, "Vancomycin in peritoneal dialysis: Clinical pharmacology considerations in therapy." (2020). *Department of Pharmacology and Experimental Therapeutics Faculty Papers*. Paper 118. https://jdc.jefferson.edu/petfp/118

This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in Department of Pharmacology and Experimental Therapeutics Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact: JeffersonDigitalCommons@jefferson.edu.

Authors

Edwin Lam, Yi Ting Kayla Lien, Walter K. Kraft, Beth Piraino, Valvanera Vozmediano, Stephan Schmidt, and Jingjing Zhang

1	Vancomycin in Peritoneal Dialysis: Clin	ical Pharmacology Considerations in Therapy
2		
3	Running title: Vancomycin in PD	
4		
5	Authors and Affiliations: Edwin Lam ¹ , N	/i Ting (Kayla) Lien ² , Walter K. Kraft ¹ , Beth Piraino ³ , Valvanera
6	Vozmediano ² , Stephan Schmidt ² , Jingjir	
7		
8	Department of Pharmacology and Expe	rimental Therapeutics, Thomas Jefferson University,
9		er for Pharmacometrics and Systems Pharmacology, Department
10	• • • • • •	, University of Florida, Lake Nona (Orlando), Florida, USA ² ; Renal
11		burgh School of Medicine, Pittsburgh, Pennsylvania, USA ³ ;
12		ephrology, Thomas Jefferson University, Philadelphia, PA, USA ⁴
	Department of Medicine, Division of Ne	ephrology, montas jenerson oniversity, Philadelphia, PA, OSA
13		
14		ported by a National Institutes of Health institutional (NIH)
15	training grant T32GM008562	
16		
17	Corresponding author:	
18	Jingjing Zhang, MD, PhD; Jingjing.zhang	
19	Department of Medicine – Division of N	lephrology
20	Thomas Jefferson University	
21	833 Chestnut East, Suite 700	
22	Philadelphia, PA 19107-5244	
23	Tel: 215-955-6550	
24	Fax: 215-503-4099	
25		
26	Manuscript Metrics	
27	Title Characters (with spaces)	82/90
28	Running Title Characters (with spaces)	16/30
29	Body of manuscript (words)	3465/4000
30	Figures	2
31	Tables	4
32	lables	4
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		

49 Abstract

50	Intraperitoneal vancomycin is the first line therapy in the management of peritoneal dialysis-related
51	peritonitis. However, due to the paucity of data, vancomycin dosing for peritonitis in patients on
52	automated peritoneal dialysis (APD) is empiric and based on clinical experience rather than evidence.
53	Studies in continuous ambulatory peritoneal dialysis (CAPD) patients have been used to provide
54	guidelines for dosing and are often extrapolated for APD use, but it is unclear if this is appropriate. This
55	review summarizes the available pharmacokinetic data used to inform optimal dosing in patients on
56	CAPD or APD. The determinants of vancomycin disposition and pharmacodynamic effects are critically
57	summarized, knowledge gaps explored, and a vancomycin dosing algorithm in peritoneal dialysis
58	patients is proposed.
59	
60	
61	
62	
63	
64	
65	
66	
67	
68	
69	
70	
71	Key words: Automated peritoneal dialysis; continuous ambulatory peritoneal dialysis; anuria; residual
72	kidney function; peritonitis; pharmacokinetics; pharmacodynamics.

73 INTRODUCTION

74 Vancomycin is often selected as empiric first line therapy for suspected Gram-positive organisms 75 in peritoneal dialysis (PD) related peritonitis. However, data on vancomycin dosing in various PD 76 modalities are limited, especially for automated peritoneal dialysis (APD). The paucity of well-designed 77 pharmacokinetic studies has led to vancomycin dosing guidelines for PD patients that are based on 78 limited information resulting in the possibility of achieving sub-or supra-therapeutic trough 79 concentrations in this special patient population.(1) 80 81 PRINCIPLES OF VANCOMYCIN THERAPY 82 Vancomycin is a tricyclic glycopeptide antibiotic with broad spectrum activity against Gram-83 *positive* bacteria. It is effective for the treatment of *Gram-positive* infections including peritonitis and is 84 the drug of choice for methicillin-resistant Staphylococcus aureus (MRSA). Vancomycin is poorly 85 absorbed following oral administration. Therefore, it is commonly administered as an intravenous 86 infusion, except in peritoneal dialysis where the route is preferentially intraperitoneal. Approximately 87 50% of vancomycin is protein-bound in plasma with a variable volume of distribution ranging between 0.4-1 L/kg in the non-PD population.(2, 3) An initial distribution half-life ranging from 30 minutes to 1 88 89 hour followed by a mean terminal elimination half-life ranging from 6-12 hours were determined 90 following intravenous dosing in patients with normal renal function.(3) Metabolism is negligible and 91 elimination occurs primarily through glomerular filtration, such that advanced renal disease substantially 92 reduces the clearance of vancomycin resulting in an elimination half-life of about 7.5 days compared to 93 4-6 hours in normal patients. This means that in patients with kidney failure, the dosing of vancomycin 94 must be adjusted.(4, 5) 95 The Clinical and Laboratory Standards Institute (CLSI) has established the vancomycin

96 breakpoint for susceptible S. aureus isolates with MIC values of $\leq 2 \text{ mg/L}$ and intermediate or resistant

for MIC values greater than 2 mg/L.(6) Despite the CLSI defined breakpoints, treatment failure for
patients infected with *S. aureus* and vancomycin MICs between 1-2 mg/L have been reported compared
to those with lower reported MICs.(7, 8) This may be due to inappropriate selection of doses that are
sufficiently high to maintain plasma concentrations that exceed the MIC.

101 To optimize the vancomycin exposure-response relationship for efficacy during S. aureus 102 infections, one must examine the ratio of the area under the concentration-time curve and the MIC 103 (AUC/MIC). Vancomycin trough concentrations between 15-20 mg/L for MIC breakpoints < 1 mg/L 104 ensures a ratio of > 400 and has been an advocated target for clinical effectiveness.(3, 9) It should be 105 noted that goal trough values recommended by consensus guidelines for efficacy may lead to 106 nephrotoxicity, which might be a consideration for patients on PD with residual kidney function.(10) This 107 however, is not well studied. In practice, clinical judgement together with therapeutic drug monitoring 108 (TDM) of steady-state vancomycin plasma concentrations is a common approach in the treatment of 109 peritonitis in PD.

110

111 PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION

112 Pharmacokinetic/pharmacodynamic modeling and simulation is an innovative approach that can 113 help inform crucial decisions, such as predicting clinical endpoints of new doses and dosing regimens or 114 optimization of drug regimens. By understanding what the body does to the drug (Pharmacokinetics) 115 and what the drug does to the body (Pharmacodynamics), dosing regimens can be tailored to the PD 116 population to avoid nephrotoxicity, retain antimicrobial eradication and suppressing the emergence of 117 resistance. Regulatory authorities mandate the submission of pharmacokinetic/pharmacodynamic 118 evaluations for drug application, which include dose evaluation in special populations. However, despite 119 the evaluation of the need of dose adjustments for patients with end stage renal disease (ESRD) - such

as those on hemodialysis- the process is not well established for old drugs. Even in those cases when
 dose adjustments are proposed for patients with ESRD, there is minimal attention in patients on PD.
 This review aims to summarize the available evidence on vancomycin pharmacokinetic and
 pharmacodynamic PD-related studies, address the physicochemical and PD modality-specific
 considerations- with attention on APD, and highlight areas where research is needed on dosing
 vancomycin for PD-related peritonitis.

126

127 VANCOMYCIN PHYSICOCHEMICAL PROPERTIES AND DRUG TRANSPORT ACROSS THE PERITONEUM

Movement of vancomycin from the peritoneum cavity to plasma is based on Fick's Law (figure 1). Middle molecular weight solutes such as vancomycin (1,486 g/mol) are dependent on dwell time during PD for absorption into the plasma. Based upon a single dose study of six non-infected subjects on PD, vancomycin has a lower dialysate to plasma ratio than urea and creatinine at two hours.(11) There is no correlation between vancomycin PD clearance and dialysis adequacy (Kt/V) following an

133 intravenous dose in patients on APD.(12)

134 Teicoplanin, a glycopeptide antibiotic with a similar molecular structure (1,564 g/mol) and 135 spectrum of activity to vancomycin, was studied in non-infected adults on continuous ambulatory 136 peritoneal dialysis (CAPD).(13) The absolute bioavailability (F_{ip}) was calculated using dialysate drug 137 concentration (corrected for amount remaining in the cavity) and drug amount sampled, which was then 138 plotted against a total dwell time of five hours. Teicoplanin systemic bioavailability, reflecting transfer 139 from the peritoneal space, was directly related to dwell time. Furthermore, the consistency in 140 absorption increased with time suggesting that complete and less variable bioavailability with 141 teicoplanin can be achieved with longer dwell times.

The rate at which vancomycin is absorbed is dependent on the permeability of the peritoneal
membrane. Vancomycin intraperitoneal to systemic transfer rate increases in patients with
inflammatory peritonitis.(14)

145

165

146 VANCOMYCIN BIOAVAILABILITY DURING CONTINUOUS AMBULATORY PERITONEAL DIALYSIS 147 Vancomycin pharmacokinetics has primarily been studied in patients on CAPD. Bioavailability 148 studies conducted in these patients typically employ a 6-hour dwell time. The F_{ip}, or the amount of 149 vancomycin reaching systemic circulation from the peritoneal space relative to an intravenous dose, is 150 approximately 50%. (15) Supporting the hypothesis of a leaky peritoneum due to membrane 151 inflammation, patients on CAPD with peritonitis have a F_{ip} of 70-91%. (14, 16) Bioavailability changes can 152 also be observed with different age cohorts. For example, in a pediatric study in children aged 5-17 years 153 old, the bioavailability was reported to be as high as about 70% in the absence of peritonitis.(17) 154 A summary of the absorption parameters from studies conducted in infected and non-infected 155 patients on CAPD is depicted in table 1. The equilibration half-life describes the time allowed for drug 156 transfer between the peritoneal space to the systemic circulation following an intraperitoneal dose of 157 vancomycin. Following intraperitoneal dosing, vancomycin equilibration half-life in patients on CAPD 158 without peritonitis was 2.9 hours and those with peritonitis 1.6-2.9 hours. (18-20) Assuming no 159 differences between peritoneum transport in those with or without peritonitis and five half-lives, 160 steady-state equilibrium between the dialytic compartment and systemic circulation would be achieved 161 following a 10-15 hour dwell. 162 163 VANCOMYCIN BIOAVAILABILITY DURING AUTOMATED PERITONEAL DIALYSIS Vancomycin possess the desired physiochemical properties as a drug candidate for 164

6

intraperitoneal administration in APD patients. In addition, with its well-established stability in PD fluids,

bioavailability is adequate as long as sufficient dwelling time is allowed for drug absorption. However,
the appropriate duration of the dwell time has not been well studied. Hence, it is crucial to monitor
vancomycin levels frequently to adjust dosing to get therapeutic concentrations in each individual
patient.

170

171 VANCOMYCIN CLEARANCE DURING PERITONEAL DIALYSIS

172 Vancomycin elimination following an intraperitoneal dose is governed by its total body 173 clearance. Total body clearance is the sum of clearances contributed from elimination organs, mainly 174 kidneys, in the case of vancomycin, and is defined as the volume of plasma cleared of vancomycin per 175 time unit. Elimination processes in PD patients include those originating from residual kidney function 176 (RKF), other non-renal sources plus the drug cleared through PD. Total body clearance is especially 177 important as it controls the overall exposure of vancomycin for the given bioavailability achieved from a 178 dwell. Dialytic clearance is defined as the volume of plasma that has been cleared of vancomycin (i.e. 179 removed from systemic circulation into the peritoneal space) by PD per unit time. Figure 1 describes the 180 various clearance processes involved in vancomycin elimination following an intraperitoneal dose. 181 Moreover, a summary of vancomycin pharmacokinetic systemic parameters is provided in table 2. 182 Vancomycin clearance in patients on PD differs among studies due to several factors including the 183 presence or absence of peritonitis, presence and extent of RKF, dwell times, dialysate volume, effect of 184 antibiotic-free PD exchanges, and age.(21) 185 186 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS

187 Continuous ambulatory peritoneal dialysis typically employs short dwell times (4-6 hours), which 188 may not be sufficient to reach equilibration between the dialysate and plasma. Studies in non-infected 189 adult CAPD patients report dialytic clearances ranging between 1.2-2.4 mL/min, which account for 20-

190	25% of the total plasma clearance. (15, 22, 23) In patients with peritonitis, vancomycin dialytic clearance
191	increases to 3.8 mL/min following a less-than five-hour exchange.(24) Clearances of up to 8.5 mL/min
192	after the first 4 hours of exchange have also been reported.(16) Vancomycin clearance through
193	elimination from the drained peritoneal dialysate contributes to 20-70% of the total plasma
194	clearance.(16, 24) As a consequence, vancomycin elimination half-life in the systemic circulation ranges
195	between 66–115 hours in patients on CAPD.(22, 24-26) One major reason in the reported variability in
196	the plasma half-life could be the difference in the sampling times which may not completely capture the
197	decline of the plasma concentrations during the terminal elimination phase. Table 2 also includes a
198	summary of above parameters in these patients.
199	

200 AUTOMATED PERITONEAL DIALYSIS

Studies conducted in the APD population are only reserved to the parenteral administration of antibiotics in patients without peritonitis, yet vancomycin is primarily used to treat peritonitis and is mostly administered intraperitoneally.(27, 28) With rapid cycling, the dialytic clearance of vancomycin may be increased. Therefore, if doses and dwell times used for those on the cycler are similar to those in CAPD, the result may be sub-therapeutic levels due to frequent exchanges.

206 To date, there has only been one study exploring intravenous vancomycin disposition in subjects 207 on APD.(12) The primary objective was to characterize vancomycin pharmacokinetic parameters in 208 adults without peritonitis after a single intravenous dose. Following the intravenous administration of 15 209 mg/kg, subjects received three cycle treatments over the course of eight hours followed by two 8-hour 210 off-cycler dwells for a total of 24 hours. A 2-liter 2.5% dextrose dialysate prescription was used during 211 and off-cycler dwell. The plasma half-life was 11.6 hours following an on-cycler exchange consisting of 212 three 2-hour dwells. When the same patients were removed from the cycler and allowed to dwell for 7-213 8 hours, the plasma half-life increased to 62.8 hours. Although vancomycin was not dosed

214 intraperitoneally in this study, rapid decline in the plasma half-life support the contribution of APD in the 215 removal of drug. Clearance values did not largely differ from those on CAPD. Approximately 30% of 216 vancomycin was removed by APD relative to the total plasma clearance, which is close to the proportion 217 reported in patients on CAPD. Although intraperitoneal vancomycin administration is recommended by 218 guidelines in patients with PD peritonitis, this intravenous administration study provides a valuable 219 insight towards drug clearance during APD.(29) It should be noted that intravenous administration of 220 vancomycin may not be adequate to achieve effective antibacterial concentrations in the 221 peritoneum.(30) 222 The current International Society for Peritoneal Dialysis (ISPD) guideline recommends 223 supplemental dosing in order to achieve plasma vancomycin troughs above 15 mg/L when administered 224 intermittently. Alternatively, temporarily switching to CAPD is another option for APD patients who 225 develop peritonitis, but is not always feasible. In patients on APD, leveraging the long dwell to

appreciate optimal vancomycin transfer is appropriate to ensure adequate time to achieve and sustain

therapeutic levels.

228

229 IMPACT OF RESIDUAL KIDNEY FUNCTION (RKF) AND TREATMENT OUTCOME

Residual kidney function in PD patients will have a profound effect for hydrophilic drugs
removed exclusively through renal filtration. Enhanced drug clearance from RKF may have implications
to treatment outcomes in patients with PD-related peritonitis. Therefore, patients with greater RKF may
require higher or more frequent antibiotic dosing.

233 require higher or more frequent antibiotic dosing.

234 The importance of RKF on the outcome of PD-related peritonitis in patients treated with

antibiotics has been discussed for more than ten years, but the data describing this relationship are still

236 scarce and controversial. The ISPD 2010 update on PD-related infections has previously recommended a

237 25% increase in antibiotic dose in patients with a daily urine output of over 100 mL.(31) This

recommendation has been removed in the updated 2016 guideline, which reflects the lack of evidence
to support this empiric recommendation.(29) In a retrospective study examining the impact of RKF on
vancomycin concentrations, the influence of RKF was found to not have a significant impact.(32)
Vancomycin concentrations appeared lower in patients who were non-anuric across both modalities
even though a 25% higher dose was administered to those with RKF. This however was concluded to not
be statistically significant. Similar results have been published showing no difference in treatment
outcomes in non-anuric and anuric patients treated with cefazolin and gentamicin.(33)

245 In contrast, a recent study investigating the relationship between RKF and PD-related peritonitis 246 treatment outcomes was able to explain treatment failures related to the remaining degree of renal 247 function.(34) Treatment failure in those with Gram-positive and culture-negative peritonitis were found 248 to be significantly higher for patients with a urinary creatinine clearance greater than 0-5 mL/min 249 compared to those who were anuric. Significantly higher relapse and recurrence were observed in those 250 patients with Gram-positive or culture-negative infections and creatinine clearances greater than 5 251 mL/min. Cefazolin and vancomycin were the main antibiotics used in the study. These observations may 252 be useful when attempting to understand the impact of RKF on treatment outcomes and raise the 253 question as to whether patients with RKF greater than 5 mL/min were under-dosed with antibiotic in 254 previous studies.

In patients treated with vancomycin, RKF may account for 10-23% of the total body clearance in PD.(12, 22) Studies examining the impact of RKF on vancomycin clearance, exposure, and treatment outcomes in PD-related peritonitis are limited. Interestingly, for the subset of patients with a glomerular filtration rate greater than 5 mL/min, RKF accounted for 39-84% of the total vancomycin clearance.(12) It would appear that the impact from RKF has a substantial effect on the total clearance of vancomycin. Thus, the recent 2016 ISPD recommendation of removing the 25% dosage increase to account for RKF is unclear as most of the studies cited accounted for a dosage increase for those who were non-anuric.(32,

35) In the absence of additional studies, dosage adjustments to account for RKF may still be appropriate as there is a substantial contribution observed on the total vancomycin clearance. For now, we can only speculate that the resulting impact in treatment failure for *Gram-positive* peritonitis may be associated with higher drug clearance values in patients with creatinine clearances greater than 5 mL/min.

266

267 THERAPEUTIC DRUG MONITORING AND PHARMACODYNAMIC RESPONSE

268 Vancomycin therapeutic drug monitoring is critical for patients with peritonitis and is routinely 269 performed because 1) the concentration plays the key component for the effect and 2) the initial 270 antibiotic dose is needed to target the maximum effect in order to allow proper eradication and 271 prevention of resistance. Moreover, the treatment window timeframe is crucial for patients. Hence, 272 appropriate plasma sampling during this timeframe is important, but may be difficult as the turnaround 273 time for assay results is a rate-limiting factor in achieving desired therapeutic drug levels. Furthermore, 274 not only is it important to ensure that the initial dose is sufficient, but also if that initial dose is able to 275 maintain therapeutic effect throughout treatment. Yet, current clinical practice is based on empirical 276 decisions, which may not reflect the most optimized regimen for patients on PD.

277 The traditional role of plasma trough concentration monitoring has been conflicting in the PD 278 population. Unlike the established optimal plasma trough levels of 10-15 mg/L for uncomplicated 279 infections or 15-20 mg/L for complicated infections, there is substantial interpatient variability for those 280 patients on PD. Higher rates of PD-related peritonitis relapse have been associated with a cumulative 4-281 week plasma trough below 12 mg/L when compared to those maintained above that threshold.(36) In 282 this study, vancomycin was given intravenously where plasma levels were maintained above 12 mg/L 283 rather than the current 15 mg/L recommendation by the ISPD. The type of modality did not differ 284 among the outcome groups, however vancomycin clearance and RKF information were not reported 285 which may have contributed to variability in the plasma concentration. On the other hand, data from a

286	single-center study involving 34 PD patients experiencing PD-related peritonitis showed no relationship
287	between plasma vancomycin levels measured during the first week and PD-related peritonitis
288	outcomes.(37) Here, CAPD was reportedly the most frequent modality (80%) used with an average
289	residual creatinine clearance of 2.8 mL/min/1.73m ² . Vancomycin was dosed based on ISPD
290	recommendations and plasma levels were maintained above 15 mg/L. Of these 34 PD patients with
291	confirmed Gram-positive infections, 43% of cases were associated with coagulase-negative
292	Staphylococcus ssp. while only 11% of cases were due to MRSA. In total, although the frequency and
293	level of vancomycin measurement was not associated with adverse clinical events during the first week
294	of treatment, the number of patients studied may be too small to draw a firm conclusion.
295	Pharmacokinetic sources of variability can be explained in part due to varying exchanges provided by the
296	patient's PD modality, impact from RKF, and peritoneum physiology affecting drug absorption. In
297	addition, the pharmacodynamics- or bacterial susceptibility measured by its MIC- contributes to the
298	variability in clinical response, which may not be explained due to vancomycin pharmacokinetics alone.
299	Taken together, vancomycin shows substantial interindividual variability in clinical response for
300	patients treated for PD-related peritonitis. Table 3 gives an overview of the
301	pharmacokinetic/pharmacodynamic factors to be considered at the time of TDM of vancomycin in
302	patients on both CAPD and APD regimens.
303	
304	CONSIDERATIONS FOR INTRAPERITONEAL DOSING
305	Clinicians should consider dwell times that achieve substantial equilibrium between the
306	peritoneum compartment and the systemic circulation. The reported bioavailabilities in literature are

- 307 dwell-time specific and may not be applicable in all patient-specific situations. Therefore, considering
- 308 the transfer half-life between the dialytic compartment and systemic circulation can be useful to
- 309 understand the time that it takes to reach equilibrium (i.e., steady-state). This may take up to 15 hours

310 considering a transfer half-life of 3 hours. (19) In this situation, dosing during the long-dwell interval may 311 provide adequate drug absorption to achieve therapeutic concentrations in plasma in patients on APD. 312 The bioavailability of vancomycin significantly increases during PD-related peritonitis. Plasma 313 concentrations as high as 40 mg/L have been reported following a 6 hour dwell using recommended 314 intraperitoneal doses of vancomycin in PD-related peritonitis.(14, 16) Alternatively, plasma 315 concentrations as low as 10 mg/L have been reported following a 6 hour dwell using a 500 mg 316 intraperitoneal dose in PD-related peritonitis. (38) Regardless of the PD modality, absorption does not 317 largely change between CAPD or APD based on the equilibration half-lives reported.(12, 19, 20) 318 In patients with PD peritonitis on APD, doses of 15-20 mg/kg together with dwell times ranging 319 from 10-15 hours may be more appropriate than the targeted concentration strategy mentioned above. 320 TDM should also be performed to evaluate therapeutic and toxic concentration fluctuations and to 321 maintain concentrations above 15 mg/L as recommended by the ISPD guidelines.

322

323 FUTURE RESEARCH AND DOSING GUIDELINES IN AUTOMATED PERITONEAL DIALYSIS

324 Empiric Gram-positive management using vancomycin for PD-related peritonitis in patients on 325 APD is summarized in figure 2. This algorithm accounts for RKF and suggests a dosage increase of 20% 326 for those who are non-anuric with a creatinine clearance greater than 5 mL/min based on observational 327 outcome studies.(34) In addition, monitoring plasma vancomycin concentrations 48 hours post-dose 328 would be appropriate based on previous experience. As such, re-dosing would be necessary to maintain 329 the targeted 15 mg/L concentration. During this time, adjustments to antibiotic therapy should be 330 guided by the microbiology or susceptibility report. This should be practiced together with routine TDM 331 at appropriate sampling times to rationally select the effective dose for each patient. Pharmacometric 332 modeling and simulation could help to increase the knowledge on vancomycin dose exposure response 333 relationship and propose optimal dosing and TDM strategies in PD patients.

As above recommendations are based on limited evidence, dedicated studies are needed to
 support them. Table 4 highlights the knowledge gaps and propose future research topics to better tailor
 vancomycin treatments in PD patients with peritonitis.

337

338 CONCLUSION

339 Optimal dosing for vancomycin should consider both the pharmacokinetic (concentration in 340 dialysis fluid and plasma), RKF, PD modality, and physicochemical factors (bioavailability, permeability) 341 and pharmacodynamics (MIC and variability to the susceptibilities of the organism). Generally, 342 vancomycin is given intraperitoneally during the long day dwell for patients on APD; this approach 343 supports adequate equilibration during the absorption phase between dialysate and plasma to reach 344 therapeutic levels. In addition, the impact of rapid cycling and RKF on the total body clearance has yet to 345 be fully defined. With this in mind, TDM may be appropriate, however, there is yet to be an established 346 protocol in PD patients with peritonitis. As the option to temporarily switch to CAPD in APD patients 347 who develop peritonitis may not be convenient, the need for future research on the impact of the cycler 348 on vancomycin clearance is imperative. Upcoming studies (NCT03685747) examining the 349 pharmacokinetic of vancomycin will address some of the knowledge gaps associated with vancomycin 350 pharmacokinetic in patients on APD. For the moment, clinicians should consider the bioavailability, 351 dwell time, and institutional microbiological susceptibilities when dosing vancomycin in PD. Dedicated 352 pharmacokinetic studies in adult and pediatric patients are needed to understand vancomycin 353 disposition in PD patients on rapid-cycling modalities. The integrated use of TDM and MICs via dosing 354 algorithms may help improve clinical outcome. 355

356

357

358 Conflict of Interests Disclosure

- No competing interests.
- 360 We have read and understood *Peritoneal Dialysis International's* policy on disclosing conflicts of interest
- and declare that we have none.

362	Refere	ences
363 364 365	1.	Salzer WL. Peritoneal dialysis-related peritonitis: Challenges and solutions. Int J Nephrol Renovasc Dis. 2018; 11:173-186.
366 367 368	2.	Marsot A, Boulamery A, Bruguerolle B, Simon N. Vancomycin: A review of population pharmacokinetic analyses. Clin Pharmacokinet. 2012; 51:1-13.
369 370 371 372 373	3.	Rybak M, Lomaestro B, Rotschafer JC, Moellering R, Jr., Craig W, Billeter M, et al. Therapeutic monitoring of vancomycin in adult patients: A consensus review of the american society of health-system pharmacists, the infectious diseases society of america, and the society of infectious diseases pharmacists. Am J Health Syst Pharm. 2009; 66:82-98.
374 375 376	4.	Matzke GR, McGory RW, Halstenson CE, Keane WF. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984; 25:433-7.
377 378 379	5.	Matzke GR, Zhanel GG, Guay DR. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet. 1986; 11:257-82.
380 381 382 383	6.	Tenover FC, Moellering RC, Jr. The rationale for revising the clinical and laboratory standards institute vancomycin minimal inhibitory concentration interpretive criteria for staphylococcus aureus. Clin Infect Dis. 2007; 44:1208-15.
384 385 386 387	7.	Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RC, Jr., Eliopoulos GM. Relationship of mic and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant staphylococcus aureus bacteremia. J Clin Microbiol. 2004; 42:2398-402.
388 389 390 391	8.	Howden BP, Ward PB, Charles PG, Korman TM, Fuller A, du Cros P, et al. Treatment outcomes for serious infections caused by methicillin-resistant staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis. 2004; 38:521-8.
392 393 394 395	9.	Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004; 43:925-42.
396 397 398	10.	Filippone EJ, Kraft WK, Farber JL. The nephrotoxicity of vancomycin. Clin Pharmacol Ther. 2017; 102:459-469.
399 400 401 402	11.	Brophy DF, Sowinski KM, Kraus MA, Moe SM, Klaunig JE, Mueller BA. Small and middle molecular weight solute clearance in nocturnal intermittent peritoneal dialysis. Perit Dial Int. 1999; 19:534-9.
403 404 405	12.	Manley HJ, Bailie GR, Frye RF, McGoldrick MD. Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients. Perit Dial Int. 2001; 21:378-85.
406 407 408	13.	Brouard RJ, Kapusnik JE, Gambertoglio JG, Schoenfeld PY, Sachdeva M, Freel K, et al. Teicoplanin pharmacokinetics and bioavailability during peritoneal dialysis. Clin Pharmacol Ther. 1989; 45:674-81.

409	14.	Morse GD, Apicella MA, Walshe JJ. Absorption of intraperitoneal antibiotics. Drug Intell Clin
410		Pharm. 1988; 22:58-61.
411		
	1 Г	Marca CD. Faralina DF. Anicalla MA. Walsha II. Comparative study of intransmitancel and
412	15.	Morse GD, Farolino DF, Apicella MA, Walshe JJ. Comparative study of intraperitoneal and
413		intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis.
414		Antimicrob Agents Chemother. 1987; 31:173-7.
415		
416	16.	Montanes Pauls B, Alminana MA, Casabo Alos VG. Vancomycin pharmacokinetics during
417		continuous ambulatory peritoneal dialysis in patients with peritonitis. Eur J Pharm Sci. 2011;
418		43:212-6.
		45.212-0.
419		
420	17.	Blowey DL, Warady BA, Abdel-Rahman S, Frye RF, Manley HJ. Vancomycin disposition following
421		intraperitoneal administration in children receiving peritoneal dialysis. Perit Dial Int. 2007;
422		27:79-85.
423		
424	18.	Rogge MC, Johnson CA, Zimmerman SW, Welling PG. Vancomycin disposition during continuous
425	10.	ambulatory peritoneal dialysis: A pharmacokinetic analysis of peritoneal drug transport.
426		Antimicrob Agents Chemother. 1985; 27:578-82.
427		
428	19.	Bailie GR, Eisele G, Venezia RA, Yocum D, Hollister A. Prediction of serum vancomycin
429		concentrations following intraperitoneal loading doses in continuous ambulatory peritoneal
430		dialysis patients with peritonitis. Clin Pharmacokinet. 1992; 22:298-307.
431		
432	20.	Neal D, Bailie GR. Clearance from dialysate and equilibration of intraperitoneal vancomycin in
433	20.	continuous ambulatory peritoneal dialysis. Clin Pharmacokinet. 1990; 18:485-90.
		continuous ambulatory peritonear dialysis. Cint marmacokinet. 1990, 18.489-90.
434	24	
435	21.	Paton TW, Cornish WR, Manuel MA, Hardy BG. Drug therapy in patients undergoing peritoneal
436		dialysis. Clinical pharmacokinetic considerations. Clin Pharmacokinet. 1985; 10:404-25.
437		
438	22.	Blevins RD, Halstenson CE, Salem NG, Matzke GR. Pharmacokinetics of vancomycin in patients
439		undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother. 1984;
440		25:603-6.
441		
442	23.	Pancorbo S, Comty C. Peritoneal transport of vancomycin in 4 patients undergoing continuous
	25.	
443		ambulatory peritoneal dialysis. Nephron. 1982; 31:37-9.
444		
445	24.	Harford AM, Sica DA, Tartaglione T, Polk RE, Dalton HP, Poynor W. Vancomycin
446		pharmacokinetics in continuous ambulatory peritoneal dialysis patients with peritonitis.
447		Nephron. 1986; 43:217-22.
448		
449	25.	Bunke CM, Aronoff GR, Brier ME, Sloan RS, Luft FC. Vancomycin kinetics during continuous
450	20.	ambulatory peritoneal dialysis. Clin Pharmacol Ther. 1983; 34:631-7.
		anibulatory peritorieal ularysis. Cili Filarinator 111e1. 1305, 54.051-7.
451	26	
452	26.	Whitby M, Edwards R, Aston E, Finch RG. Pharmacokinetics of single dose intravenous
453		vancomycin in capd peritonitis. J Antimicrob Chemother. 1987; 19:351-7.
454		

455 27. Tobudic S, Matzneller P, Stoiser B, Wenisch JM, Zeitlinger M, Vychytil A, et al. Pharmacokinetics 456 of intraperitoneal and intravenous fosfomycin in automated peritoneal dialysis patients without 457 peritonitis. Antimicrob Agents Chemother. 2012; 56:3992-5. 458 459 28. Wiesholzer M, Pichler P, Reznicek G, Wimmer M, Kussmann M, Balcke P, et al. An open, 460 randomized, single-center, crossover pharmacokinetic study of meropenem after 461 intraperitoneal and intravenous administration in patients receiving automated peritoneal 462 dialysis. Antimicrob Agents Chemother. 2016; 60:2790-7. 463 464 29. Li PK, Szeto CC, Piraino B, de Arteaga J, Fan S, Figueiredo AE, et al. Ispd peritonitis 465 recommendations: 2016 update on prevention and treatment. Perit Dial Int. 2016; 36:481-508. 466 467 30. Cardone KE, Chen WZ, Grabe DW, Batzold A, Manley HJ, Lodise TP. Evaluation of the 468 pharmacodynamic profile of commonly used intravenous vancomycin dosing schemes in 469 patients on automated peritoneal dialysis. J Antimicrob Chemother. 2014; 69:1873-6. 470 471 31. Li PK, Szeto CC, Piraino B, Bernardini J, Figueiredo AE, Gupta A, et al. Peritoneal dialysis-related 472 infections recommendations: 2010 update. Perit Dial Int. 2010; 30:393-423. 473 474 32. Blunden M, Zeitlin D, Ashman N, Fan SL. Single uk centre experience on the treatment of pd 475 peritonitis--antibiotic levels and outcomes. Nephrol Dial Transplant. 2007; 22:1714-9. 476 477 33. Tosukhowong T, Eiam-Ong S, Thamutok K, Wittayalertpanya S, Na Ayudhya DP. 478 Pharmacokinetics of intraperitoneal cefazolin and gentamicin in empiric therapy of peritonitis in 479 continuous ambulatory peritoneal dialysis patients. Perit Dial Int. 2001; 21:587-94. 480 481 34. Whitty R, Bargman JM, Kiss A, Dresser L, Lui P. Residual kidney function and peritoneal dialysis-482 associated peritonitis treatment outcomes. Clin J Am Soc Nephrol. 2017; 12:2016-2022. 483 484 35. Fish R, Nipah R, Jones C, Finney H, Fan SL. Intraperitoneal vancomycin concentrations during 485 peritoneal dialysis-associated peritonitis: Correlation with serum levels. Perit Dial Int. 2012; 486 32:332-8. 487 Mulhern JG, Braden GL, O'Shea MH, Madden RL, Lipkowitz GS, Germain MJ. Trough serum 488 36. 489 vancomycin levels predict the relapse of gram-positive peritonitis in peritoneal dialysis patients. 490 Am J Kidney Dis. 1995; 25:611-5. 491 492 37. Stevenson S, Tang W, Cho Y, Mudge DW, Hawley CM, Badve SV, et al. The role of monitoring 493 vancomycin levels in patients with peritoneal dialysis-associated peritonitis. Perit Dial Int. 2015; 494 35:222-8. 495 496 38. Brown J, Altmann P, Cunningham J, Shaw E, Marsh F. Pharmacokinetics of once daily intra-497 peritoneal aztreonam and vancomycin in the treatment of capd peritonitis. J Antimicrob 498 Chemother. 1990; 25:141-7. 499 500 39. Gendeh BS, Gibb AG, Aziz NS, Kong N, Zahir ZM. Vancomycin administration in continuous 501 ambulatory peritoneal dialysis: The risk of ototoxicity. Otolaryngol Head Neck Surg. 1998; 502 118:551-8. 503

Adults							
Infection	Dose	Dwell Time (hours)	Bioavailability (%)	Dosing	Plasma Concentration		
Status					(mg/L)	Time of sampling (hour)	Reference
Nogativo	30 mg/kg	6	49	Single	24.9	6	[15]
Negative	10 mg/kg	4	65	Single	6.3	5	[25]
	30 mg/kg	6	91	Single	40	4	[14]
	2 g	6	70	Single	39.7	6	[16]
PD- Peritonitis	500 mg	6	83	Multiple	10.2	6	[38]
Pentonitis	15 mg/kg	4	66	Single	16.1	6	[19]
	30 mg/kg	10-12	N/A	Multiple	33.8	12	[39]
Pediatric							
		Dose Dwell Time	Bioavailability (%)	Dosing	Plasma Concentration		
Infection	Dose				(mg/L)	Time of sampling	Reference
Negative	550 mg/m ²	6	70	Single	23.3	6	[17]

Table 1. Vancomycin absorption parameters in adult and pediatric non-infected and PD-related peritonitis patients on peritoneal dialysis.

505 N/A = not reported

510 **Table 2.** Vancomycin distribution and clearance parameters in adult and pediatric non-infected and PD-related peritonitis patients on CAPD or

511 APD.

Adults	1		1		1			Γ
Modality	Infection Status	Route	Vd (L/kg)	Plasma Half- life (hours)	Clearance (mL/min)			Deference
would ty					Total	Dialytic	Renal	Reference
	Negative	IP	0.56	111	5	1.2	N/A	[15]
		IV	0.73	92	6.4	1.4	0.65	[22]
64.DD		IP	0.61	N/A	N/A	15.7	N/A	[19]
CAPD	PD-Peritonitis	IP	0.87	N/A	8.5	12.2	N/A	[20]
		IV	0.55	104	4.1	3.8	N/A	[24]
		IV	1.1	115	7.2	1.4	N/A	[26]
APD	Negative	IV	0.4	11.6 / 62.8ª	7.4	2.1	1.7	[12]
Pediatric								
		D. I.		g) Plasma	Clearance (mL/min/1.73m ²)			
Modality	Infection	Route V _c	V _d (L/kg)		Total	Dialytic	Renal	Reference
CAPD		IP	0.48	25	10.7	2.5	1.4	[17]
APD	– Negative	IP 0.48		25	14.9	3.1	1.4	[17]

512

2 ^aHalf-life during the ambulatory CAPD portion of the study. APD = automated peritoneal dialysis, CAPD = continuous ambulatory peritoneal dialysis,

513 N/A = not reported, V_d = volume of distribution

515 **Table 3.** Pharmacokinetic/pharmacodynamic factors for TDM consideration between CAPD and APD vancomycin regimens.


Pharmacokinetic/pharmacodynamics	PD components	CAPD	APD		
Absorption	Dwell time	\downarrow Bioavailability	个 Bioavailability		
Absorption	Dosing route (IP vs. IV)	vs. IV) Same			
	Permeability (Peritonitis vs. non-peritonitis)				
	Diffusion				
Distribution	Protein binding	Same			
	Surface area				
	Vascularity				
	Dosing route (IP vs. IV)	RKF- Drives variation in systemic circulation			
	Body size & Dialysate volume	Same- Patient dependent			
Elimination	Dwell time	↑ Clearance \downarrow Clearance			
	Number of non-antibiotic exchanges	↓ Clearance	个 Clearance		
Pharmacodynamics	MIC/AUC	Same- Suscep	otibility report		

516 APD = Automated peritoneal dialysis, AUC = area under the vancomycin plasma-concentration time curve, CAPD = continuous ambulatory 517 peritoneal dialysis, IP = intraperitoneal, IV = intravenous, MIC = minimal inhibitor concentration, PD = peritoneal dialysis, RKF = residual kidney 518 function


519

Table 4. Proposal for critical research areas to optimize vancomycin therapy in peritoneal dialysis.

Pr	roposal for Critical Research Areas of Needed Research for Vancomycin Therapy in Peritoneal Dialysis
•	Effect of APD on peritoneal and plasma levels during rapid cycles
•	Peak concentration following absorption from the long-dwell
•	Optimal trough concentrations associated with improved clinical outcomes and the timing of trough monitoring specific for the peritoneal dialysis population
•	Dosing regimen to achieve optimal trough concentrations
•	Effect of residual kidney function on vancomycin disposition and its implications on dosing
•	Factors affecting non-renal and non-dialytic clearance of vancomycin
■ AP[Determining appropriate clinical plasma sampling time points D = Automated Peritoneal Dialysis



- 541 **Figure 1.** Illustration of vancomycin absorption, distribution and elimination following an intraperitoneal dose.
- 542 Increasing the dwell time enhances vancomycin bioavailability. Peritoneum and dialysate properties should be considered as these both affect the
- rate and extent of absorption following an intraperitoneal dose. Following dosing and an appreciable dwell time, vancomycin is eliminated by PD,
- renal, and non-renal sources. These processes make up the total body clearance of vancomycin.
- 545 This illustration is a derivative of "Simple squamous epithelium", "Arteries", "Arterial circulation" and "Bubble" by Servier Medical Art
- 546 (https://smart.servier.com/) under the Creative Commons License (CC BY 3.0).



559 **Figure 2.** Proposed vancomycin dosing and monitoring algorithm in patients on automated peritoneal dialysis.

560 Vancomycin dosing in patients on APD with peritonitis should follow the recommended 15-20 mg/kg dose administered intraperitoneally. For

- those who are non-anuric with creatinine clearances > 5 mL/min, a 20% increase in the calculated dose is suggested. A vancomycin level should
- 562 be obtained 48 hours post-dose. Dosage adjustments and monitoring should be based on clinical response and microbiological susceptibility

563 reports.